TherapeuticsMD, Inc. Cash and Restricted Cash
TherapeuticsMD, Inc. (TXMD) had Cash and Restricted Cash of $9.19 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9.19M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8.42M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.48M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.12M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $9.19M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $8.42M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $7.48M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $7.12M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $6.07M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $5.75M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $5.06M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | $5.05M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $5.23M 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $4.34M 10-Q · filed 2025-05-13 | |
| 2023-12-31 | $4.33M 10-K/A · filed 2026-04-01 | |
| 2023-09-30 | $49.32M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $13.73M 10-Q · filed 2024-08-12 | $49.32M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $49.32M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $49.32M 10-K · filed 2025-03-27 | $64.91M 10-K · filed 2023-04-07 |
| 2022-09-30 | $65.12M 10-Q · filed 2023-11-14 | $38.33M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $65.12M 10-Q · filed 2023-08-14 | $37.55M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $65.12M 10-Q · filed 2023-05-15 | $30.38M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $64.91M 10-K · filed 2024-03-29 | $65.12M 10-K · filed 2022-03-23 |
| 2021-09-30 | $104.84M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $111.42M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $137.62M 10-Q · filed 2022-05-16 | |
| 2020-12-31 | $80.49M 10-Q · filed 2022-11-14 | $80.49M 10-K · filed 2021-03-04 |
| 2020-09-30 | $79.63M 10-Q · filed 2021-11-12 | $79.63M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $113.84M 10-Q · filed 2021-08-04 | $113.84M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $170.10M 10-Q · filed 2021-05-06 | $170.10M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $160.83M 10-K · filed 2022-03-23 | $160.83M 10-K · filed 2020-02-24 |
| 2019-09-30 | $155.33M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $182.85M 10-Q · filed 2020-08-07 | |
| 2019-03-31 | $122.88M 10-Q · filed 2020-05-06 | |
| 2018-12-31 | $161.61M 10-K · filed 2022-03-23 | $161.61M 10-Q · filed 2019-11-08 |
| 2018-09-30 | $190.00M 10-Q · filed 2019-11-08 | |
| 2017-12-31 | $127.14M 10-K · filed 2021-03-04 | |
| 2016-12-31 | $131.53M 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |